Novo Nordisk will slash insulin prices next year, following a path set by rival Eli Lilly. Patients have long called for insulin price cuts. High insulin prices force many people to ration doses, which can be dangerous for their health. Insulin prices have more than tripled in the last two decades. —npr.org